127 related articles for article (PubMed ID: 25716707)
21. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
Imazeki F; Yokosuka O; Fukai K; Saisho H
Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
Cacoub P; Nahon P; Layese R; Blaise L; Desbois AC; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Zucman D; Di Martino V; Bagnis CI; Ziol M; Sutton A; Letouze E; Roudot-Thoraval F; Audureau E;
Am Heart J; 2018 Apr; 198():4-17. PubMed ID: 29653647
[TBL] [Abstract][Full Text] [Related]
23. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
[TBL] [Abstract][Full Text] [Related]
24. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C.
Vergniol J; Boursier J; Coutzac C; Bertrais S; Foucher J; Angel C; Chermak F; Hubert IF; Merrouche W; Oberti F; de Lédinghen V; Calès P
Hepatology; 2014 Jul; 60(1):65-76. PubMed ID: 24519328
[TBL] [Abstract][Full Text] [Related]
25. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.
Hui JM; Kench JG; Chitturi S; Sud A; Farrell GC; Byth K; Hall P; Khan M; George J
Hepatology; 2003 Aug; 38(2):420-7. PubMed ID: 12883486
[TBL] [Abstract][Full Text] [Related]
28. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
29. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
30. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.
Singal AG; Volk ML; Jensen D; Di Bisceglie AM; Schoenfeld PS
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):280-8, 288.e1. PubMed ID: 19948249
[TBL] [Abstract][Full Text] [Related]
31. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
32. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
Shili-Masmoudi S; Sogni P; de Ledinghen V; Esterle L; Valantin MA; Poizot-Martin I; Simon A; Rosenthal E; Lacombe K; Pialoux G; Bouchaud O; Gervais-Hasenknoff A; Goujard C; Piroth L; Zucman D; Dominguez S; Raffi F; Alric L; Bani-Sadr F; Lascoux-Combe C; Garipuy D; Miailhes P; Vittecoq D; Duvivier C; Aumaître H; Neau D; Morlat P; Dabis F; Salmon D; Wittkop L;
PLoS One; 2019; 14(1):e0211286. PubMed ID: 30682180
[TBL] [Abstract][Full Text] [Related]
33. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy.
Alfaleh FZ; Alswat K; Helmy A; Al-hamoudi W; El-sharkawy M; Omar M; Shalaby A; Bedewi MA; Hadad Q; Ali SM; Alfaleh A; Abdo AA
Liver Int; 2013 Jul; 33(6):871-83. PubMed ID: 23490034
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
[TBL] [Abstract][Full Text] [Related]
35. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
[TBL] [Abstract][Full Text] [Related]
36. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Carrero A; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Tural C; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Barquilla E; Bellón JM; González-García J;
J Hepatol; 2013 Jun; 58(6):1104-12. PubMed ID: 23395690
[TBL] [Abstract][Full Text] [Related]
37. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
[TBL] [Abstract][Full Text] [Related]
38. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
39. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
[TBL] [Abstract][Full Text] [Related]
40. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
